( NASDAQ-NMS:AMGN )

News from Amgen A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 08, 2018, 01:00 ET European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing...


Jan 05, 2018, 09:00 ET FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...


Jan 04, 2018, 16:00 ET Amgen To Present At The 36th Annual J.P. Morgan Healthcare Conference

Amgen (NASDAQ: AMGN) will present at the 36th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 9, 2018, in San Francisco....


Dec 14, 2017, 16:00 ET Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral

Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two...


Dec 12, 2017, 16:00 ET Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. The dividend...


Dec 11, 2017, 16:00 ET KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE...


Dec 11, 2017, 09:00 ET Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires

Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this...


Dec 07, 2017, 09:00 ET New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers

Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved...


Dec 06, 2017, 16:00 ET Amgen To Webcast Investor Call At ASH 2017

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting &...


Dec 01, 2017, 16:00 ET FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke

Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug...


Nov 29, 2017, 17:00 ET Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

Amgen (NASDAQ: AMGN) today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE...


Nov 27, 2017, 16:00 ET Amgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

Amgen (NASDAQ:AMGN) will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, Nov. 30, 2017, in Boston, beginning...


Nov 23, 2017, 13:30 ET Estudo mostra que Repatha® (evolocumabe) reduz pela metade o risco relativo de eventos cardiovasculares em pacientes com doença arterial periférica

A Amgen, biofarmacêutica focada no desenvolvimento de medicamentos para doenças de difícil tratamento, apresentou durante o congresso da American...


Nov 17, 2017, 09:00 ET Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients

Amgen (NASDAQ:AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation...


Nov 13, 2017, 16:00 ET New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks

Amgen (NASDAQ:AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that...


Nov 10, 2017, 07:29 ET Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura

Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...


Nov 10, 2017, 07:27 ET Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...


Nov 06, 2017, 09:00 ET Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017

Amgen (NASDAQ: AMGN) today announced new analyses will be presented from the Repatha® (evolocumab) cardiovascular outcomes study, including...


Nov 02, 2017, 16:30 ET Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program

Amgen (NASDAQ:AMGN) and Novartis today announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial –...


Oct 31, 2017, 02:30 ET Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen

Amgen (NASDAQ:AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies,...


Oct 25, 2017, 16:01 ET Amgen Reports Third Quarter 2017 Financial Results

Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2017. Key results include: - Total revenues...


Oct 24, 2017, 16:34 ET Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors

Amgen (NASDAQ:AMGN) today announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee...


Oct 24, 2017, 16:00 ET Amgen Announces 2017 Fourth Quarter Dividend

Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the fourth quarter of 2017. The dividend...


Oct 24, 2017, 09:00 ET Award-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch 'At Home With Joan' To Empower Patients Battling Cancer

Amgen (NASDAQ:AMGN) today announced the launch of At Home with Joan, a campaign led by breast cancer survivor and advocate Joan Lunden. This...


Oct 23, 2017, 16:00 ET Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients

Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered...